Tags

Type your tag names separated by a space and hit enter

Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
Clin Neuropharmacol. 1993; 16 Suppl 2:S51-4.CN

Abstract

Brofaromine is a new, reversible, and selective type-A monoamine oxidase inhibitor (MAOI) that also has serotonin reuptake inhibitory properties. Its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs. A multicenter, double-blind, placebo-controlled study including 220 patients was undertaken to evaluate the efficacy and safety of brofaromine in major depression. This study of a fixed-dose design and 6 weeks' duration found that brofaromine was significantly better than placebo on the Overall Evaluation of Efficacy, Beck self-rating scale, HAM-D Bech subscale, HAM-D total 14 items (minus the three sleep items), HAM-D depressed mood item and retardation factor, and worse than placebo on the insomnia items of HAM-D. Significantly more patients on placebo than on brofaromine did not complete the trial due to lack of efficacy. In comparative controlled studies (n = 899), brofaromine was found to be at least as efficacious as tricyclic antidepressants (imipramine) and standard MAOIs (tranylcypromine and phenelzine). Reductions of at least 50% in the HAM-D total score were seen in 58-66% of patients treated with either brofaromine or imipramine (n = 609). Brofaromine also was found to be of comparable efficacy to tranylcypromine in two clinical trials (n = 132), one of which included patients considered to have a treatment-resistant depression (n = 39). In another double-blind study that compared brofaromine (150 mg/day) to phenelzine (45 mg/day) (n = 158), there was no difference between brofaromine and phenelzine.

Authors+Show Affiliations

Hôpital Louis-H. Lafontaine, Montreal, Quebec, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

8313397

Citation

Chouinard, G, et al. "Brofaromine in Depression: a Canadian Multicenter Placebo Trial and a Review of Standard Drug Comparative Studies." Clinical Neuropharmacology, vol. 16 Suppl 2, 1993, pp. S51-4.
Chouinard G, Saxena BM, Nair NP, et al. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol. 1993;16 Suppl 2:S51-4.
Chouinard, G., Saxena, B. M., Nair, N. P., Kutcher, S. P., Bakish, D., Bradwejn, J., Kennedy, S. H., Sharma, V., Remick, R. A., & Kukha-Mohamad, S. A. (1993). Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clinical Neuropharmacology, 16 Suppl 2, S51-4.
Chouinard G, et al. Brofaromine in Depression: a Canadian Multicenter Placebo Trial and a Review of Standard Drug Comparative Studies. Clin Neuropharmacol. 1993;16 Suppl 2:S51-4. PubMed PMID: 8313397.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. A1 - Chouinard,G, AU - Saxena,B M, AU - Nair,N P, AU - Kutcher,S P, AU - Bakish,D, AU - Bradwejn,J, AU - Kennedy,S H, AU - Sharma,V, AU - Remick,R A, AU - Kukha-Mohamad,S A, PY - 1993/1/1/pubmed PY - 1993/1/1/medline PY - 1993/1/1/entrez SP - S51 EP - 4 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 16 Suppl 2 N2 - Brofaromine is a new, reversible, and selective type-A monoamine oxidase inhibitor (MAOI) that also has serotonin reuptake inhibitory properties. Its dual pharmacologic effects offer promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with standard drugs. A multicenter, double-blind, placebo-controlled study including 220 patients was undertaken to evaluate the efficacy and safety of brofaromine in major depression. This study of a fixed-dose design and 6 weeks' duration found that brofaromine was significantly better than placebo on the Overall Evaluation of Efficacy, Beck self-rating scale, HAM-D Bech subscale, HAM-D total 14 items (minus the three sleep items), HAM-D depressed mood item and retardation factor, and worse than placebo on the insomnia items of HAM-D. Significantly more patients on placebo than on brofaromine did not complete the trial due to lack of efficacy. In comparative controlled studies (n = 899), brofaromine was found to be at least as efficacious as tricyclic antidepressants (imipramine) and standard MAOIs (tranylcypromine and phenelzine). Reductions of at least 50% in the HAM-D total score were seen in 58-66% of patients treated with either brofaromine or imipramine (n = 609). Brofaromine also was found to be of comparable efficacy to tranylcypromine in two clinical trials (n = 132), one of which included patients considered to have a treatment-resistant depression (n = 39). In another double-blind study that compared brofaromine (150 mg/day) to phenelzine (45 mg/day) (n = 158), there was no difference between brofaromine and phenelzine. SN - 0362-5664 UR - https://www.unboundmedicine.com/medline/citation/8313397/Brofaromine_in_depression:_a_Canadian_multicenter_placebo_trial_and_a_review_of_standard_drug_comparative_studies_ L2 - http://www.diseaseinfosearch.org/result/2199 DB - PRIME DP - Unbound Medicine ER -